Skip to main content

Table 3 Meta-regression analysis for the effect of metformin on SMCC of cardiovascular parameters and NT-ProBNP

From: Effect of metformin on left ventricular mass and functional parameters in non-diabetic patients: a meta-analysis of randomized clinical trials

  LVMI LVEF E/e′ ratio NT-ProBNP/BNP
B [95% CI] p B [95% CI] p B [95% CI] p B [95% CI] p
Intercept only model  − 0.49 [− 0.94; − 0.04] 0.036 0.128 [–0.19; 0.45] 0.45 –0.18 [− 0.387; 0.03] 0.07  − 0.07 [− 0.28; 0.14] 0.44
Metformin dose
 1000 mg or less  − 0.287 [–0.7; 0.134] 0.14 –0.23 [− 0.49; 0.03] 0.07  − 0.128 [− 0.59; 0.34] 0.36 NA  
  > 1000 mg  − 0.7 [− 1.51;0.11] 0.08 0.28 [0.04; 0.52] 0.04  − 0.313 [− 1.2; 0.56] 0.26  − 0.02 [− 0.44; 0.41] 0.92
Duration
 6 months or less  − 0.215 [− 0.51; 0.08] 0.12  − 0.02 [− 0.48; 0.43] 0.9  − 0.163 [− 0.5; 0.17] 0.17  − 0.05 [− 0.5; 0.41] 0.79
  > 6 months  − 0.4 [− 0.78; − 0.02] 0.04 0.3 [− 0.07; 0.68] 0.09 NA    − 0.07 [− 0.36; 0.21] 0.53
HF
 No  − 0.51 [− 1.1; 0.08] 0.09 0.06 [− 0.5; 0.62] 0.81  − 0.19 [− 0.73; 0.36] 0.28  − 0.04 [− 0.26; 0.19] 0.68
 Yes NA   0.23 [0.1; 0.36] 0.004 NA    − 0.08 [− 0.73; 0.56] 0.74
Pooled baseline average (1 unit increase) 0.005 [− 0.02; 0.03] 0.64  − 0.005 [− 0.02; 0.01] 0.34 0.05 [− 0.13; 0.23] 0.35 0.09 ¶ [− 0.05; 0.06] 0.69
  1. Bold values denote statistical significance at the p < 0.05 level
  2. B—regression coefficient (SMCC), CI.L—lower limit for 95% confidence interval, CI.U—upper limit for the 95% confidence interval
  3. HF heart failure
  4. NA: Only one study provided data
  5. Result represents the change in SMCC for each 100-unit increase